Mutation and Expression of TP53 in Malignant Melanomas

Johannes M. Weiss(University Hospital Ulm), E. G. Jung(Heidelberg University), Henryk Pilch(Heidelberg University), Brigitte H. Körner(Heidelberg University), M Heine(Heidelberg University), Karen C. Arden(Ludwig Cancer Research), Rudolf Herbst(Helios Klinikum Erfurt)

Recent results in cancer research/Recent Results in Cancer Research

January 1, 1995

10.1007/978-3-642-78771-3_10

Cited by 51

Related Papers

Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial

|The Lancet Oncology|2016|704

Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal Melanoma

|PLoS ONE|2015|292

Final Analysis of DeCOG-SLT Trial: No Survival Benefit for Complete Lymph Node Dissection in Patients With Melanoma With Positive Sentinel Node

|Journal of Clinical Oncology|2019|254

Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial

|The Lancet|2020|242

Ablation of PDK1 in pancreatic β cells induces diabetes as a result of loss of β cell mass

|Nature Genetics|2006|224